Your browser doesn't support javascript.
loading
Dicloxacillin is an inducer of intestinal P-glycoprotein but neither dicloxacillin nor flucloxacillin increases the risk of stroke/systemic embolism in direct oral anticoagulant users.
Iversen, Ditte B; Dunvald, Ann-Cathrine Dalgård; Ernst, Martin Thomsen; Abtahi, Shahab; Souverein, Patrick; Klungel, Olaf; Jeppesen, Glenn Brøde; Nielsen, Flemming; Brøsen, Kim; Hammer, Helen S; Pötz, Oliver; Damkier, Per; Järvinen, Erkka; Pottegård, Anton; Stage, Tore B.
Afiliación
  • Iversen DB; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Dunvald AD; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Ernst MT; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Abtahi S; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands.
  • Souverein P; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands.
  • Klungel O; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Jeppesen GB; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands.
  • Nielsen F; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Brøsen K; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Hammer HS; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark.
  • Pötz O; Signatope GmbH, Reutlingen, Germany.
  • Damkier P; Signatope GmbH, Reutlingen, Germany.
  • Järvinen E; NMI Natural and Medical Sciences Institute at the University of Tuebingen, Reutlingen, Germany.
  • Pottegård A; Department of Clinical Pharmacology, Odense University Hospital, Odense, Denmark.
  • Stage TB; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Br J Clin Pharmacol ; 2024 Aug 19.
Article en En | MEDLINE | ID: mdl-39160000
ABSTRACT

AIM:

We aimed to assess if dicloxacillin/flucloxacillin reduces the therapeutic efficacy of direct oral anticoagulants (DOACs) and the underlying molecular mechanism.

METHODS:

In a randomized, crossover study, we assessed whether dicloxacillin reduces oral absorption of drugs through P-glycoprotein (P-gp) during 10 and 28 days of treatment. To study the impact of dicloxacillin/flucloxacillin on intestinal and hepatic expression of P-gp in vitro, we usd LS174T cells and 3D spheroids of primary human hepatocytes. Finally, we used nationwide Danish health registries and the UK's Clinical Practice Research Datalink to estimate hazard ratios (HRs) for the risk of stroke and systemic embolism following dicloxacillin/flucloxacillin exposure among DOAC users, using phenoxymethylpenicillin and amoxicillin as active comparators.

RESULTS:

Dicloxacillin reduced the area under the curve of dabigatran to a geometric mean ratio 10 days of 0.67 (95% confidence interval [CI] 0.42-1.1) and geometric mean ratio 28 days of 0.72 (95% CI 0.39-1.4), suggesting reduced oral absorption via increased P-gp expression. In vitro, dicloxacillin raised P-gp expression in both intestinal and liver cells, while flucloxacillin only affected liver cells. In the pharmacoepidemiologic study, dicloxacillin and flucloxacillin were not associated with increased risk of stroke/systemic embolism (dicloxacillin vs. phenoxymethylpenicillin HR 0.93, 95% CI 0.72-1.2; flucloxacillin vs. amoxicillin HR 0.89, 95% CI 0.51-1.5).

CONCLUSIONS:

Dicloxacillin increases expression of intestinal P-gp, leading to reduced oral absorption of dabigatran. However, concomitant use of dicloxacillin/flucloxacillin was not associated with stroke and systemic embolism among DOAC users, suggesting no clinical impact from the drug-drug interaction between dicloxacillin/flucloxacillin and DOACs.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Br J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Br J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Reino Unido